Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wolters, E. Ch.
Right arrow Articles by Sennef, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wolters, E. Ch.
Right arrow Articles by Sennef, C.
NEUROLOGY 1990;40:1099
© 1990 American Academy of Neurology

DGAVP (Org 5667) in early Alzheimer's disease patients

An international double-blind, placebo-controlled, multicenter trial

E. Ch. Wolters, MD, P. Riekkinen, MD, A. Lowenthal, MD, J. J. Van der Plaats, MD, J.M.T. Zwart, MD and C. Sennef, PhD

Departments of Neurology, Amsterdam Free University (Dr. Wolters), Amsterdam, The Netherlands; the University of Kuopio (Dr. Riekkinen), Kuopio, Finland; the University of Antwerp, General Hospital Middelheim (Dr. Lowenthal), Antwerp, Belgium; the University of Nijmegen (Dr. Van der Plaats), Nijmegen, The Netherlands; St. Lambertus Hospital (Dr. Zwart), Helmond, The Netherlands; and AKZO Organon (Dr. Sennef), Oss, The Netherlands.

We carried out a double-blind study of a vasopressin-related peptide, DGAVP citrate (Org 5667), in 115 patients with mild dementia, probable Alzheimer's type (DAT). Neither clinical rating scales nor psychometric tests revealed any improvement over 84 days with once-daily intranasal treatment with 2 different doses of DGAVP. We conclude that vasopressin-like peptides are not satisfactory therapeutic agents in DAT.

Address correspondence and reprint requests to Dr. E.Ch. Wolters, Department of Neurology, Academic Hospital, Amsterdam Free University Hospital, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands.

Received September 12, 1989. Accepted for publication in final form December 14, 1989.




This article has been cited by other articles:


Home page
 NeurologyHome page
R. S. Doody, J.C. Stevens, C. Beck, R.M. Dubinsky, J.A. Kaye, L. Gwyther, R.C. Mohs, L.J. Thal, P.J. Whitehouse, S.T. DeKosky, et al.
Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurology, May 8, 2001; 56(9): 1154 - 1166.
[Abstract] [Full Text] [PDF]

Home page
 J Geriatr Psychiatry NeurolHome page
S. V. Patel
Pharmacotherapy of Cognitive Impairment in Alzheimer's Disease: A Review
J Geriatr Psychiatry Neurol, April 1, 1995; 8(2): 81 - 95.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1990 by AAN Enterprises, Inc.